SCHEMBL13380604

SCHEMBL13380604

CC(=N)/C(C#N)=C1/Nc2ccccc2S1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 7/20 0.55
SMN1; SMN2 Q16637 5/20 0.55
RAB9A P51151 3/20 0.55
ALDH1A1 P00352 3/20 0.55
NPC1 O15118 2/20 0.55
HIF1A Q16665 1/20 0.55
NOX1 Q9Y5S8 9/20 0.43
MAPT P10636 7/20 0.43
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
ALOX15 P16050 2/20 0.43
SNCA P37840 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
BCHE P06276 2/20 0.43
ACHE P22303 2/20 0.43
CYP1A2 P05177 1/20 0.43
POLB P06746 1/20 0.43
CYP3A4 P08684 1/20 0.43
ADORA3 P0DMS8 1/20 0.43
ALOX12 P18054 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL78262 0.85 GAA (0.55) GAASMN1; SMN2RAB9AALDH1A1NPC1
SCHEMBL78263 0.85 GAA (0.55) GAASMN1; SMN2RAB9AALDH1A1NPC1
SCHEMBL10105463 0.85 GAA (0.55) GAASMN1; SMN2RAB9AALDH1A1NPC1
SCHEMBL13765723 0.81 GAA (0.50) GAASMN1; SMN2RAB9AALDH1A1NPC1
SCHEMBL78367 0.80 GAA (0.64) GAASMN1; SMN2RAB9AALDH1A1NPC1
SCHEMBL78368 0.80 GAA (0.64) GAASMN1; SMN2RAB9AALDH1A1NPC1
SCHEMBL79019 0.79 GAA (0.62) GAASMN1; SMN2RAB9AALDH1A1NPC1
SCHEMBL79018 0.79 GAA (0.62) GAASMN1; SMN2RAB9AALDH1A1NPC1
SCHEMBL14079780 0.78 GAA (0.58) GAASMN1; SMN2RAB9AALDH1A1NPC1
SCHEMBL76412 0.77 GAA (0.56) GAASMN1; SMN2RAB9AALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100081653-A1 2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors TELIK, INC. 2010-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081653-A1 2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors MAP3K2, MAP4K2, MAP3K12 GAA 2073/4885SMN1; SMN2 3379/4885RAB9A 3879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.